ClinicalTrials.gg
CompletedNCT00322842Updated Mar 13, 2014Results posted

Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients

A Phase 2 interventional study of G-CSF Plus Plerixafor in Lymphoma, Non-Hodgkin and Multiple Myeloma, sponsored by Genzyme, a Sanofi Company. Completed at 3 sites in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-03-13.

Sponsored by Genzyme, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing Granulocyte Colony-Stimulating Factor in Lymphoma, Non-Hodgkin — 1 open to participants now, 1 under way, none of them phase 3. Granulocyte Colony-Stimulating Factor · Lymphoma, Non-Hodgkin.

Enrollment
11th of 19
35 · median 36
Started
2004
with 4 others
Phase 2
15 of 19
1 open now
Registered
3rd of 19
by date
Lead sponsor
8 of 19
Genzyme, a Sanofi Company

Among the 19 studies testing Granulocyte Colony-Stimulating Factor in Lymphoma, Non-Hodgkin, this one is the 11th largest by enrollment, is one of 5 that started in 2004, is one of 15 in phase 2, and was the 3rd registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

1 of the 19 studies testing Granulocyte Colony-Stimulating Factor in Lymphoma, Non-Hodgkin is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About Granulocyte Colony-Stimulating Factor

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing Granulocyte Colony-Stimulating Factor in Lymphoma, Non-Hodgkin, or all of them as a file.
02

Study summary

This study evaluates the safety of plerixafor and other outcomes that are purely exploratory in nature. One other pre-specified outcome is to evaluate an interval of 10-11 hours between dosing with plerixafor and the beginning of apheresis to determine if there will be at least a 2-fold increase in circulating CD34+ cells. Data from this protocol will assist in the determination of the dosing schedule for future studies.

Read the detailed description

Participants with non-Hodgkin's lymphoma and multiple myeloma who have undergone prior cyto-reductive chemotherapy and are to be autologously transplanted will be treated with a combination of plerixafor and granulocyte colony-stimulating factor (G-CSF) mobilization regimen on the day prior to apheresis. The only change to standard of European care is the addition of plerixafor to a G-CSF mobilizing regimen. Participants will undergo mobilization with G-CSF (10 µg/kg each day) and on each day prior to apheresis will receive plerixafor (240 µg/kg). Participants will undergo apheresis for up to 5 consecutive days in order to collect the target number of (≥ 5*10\^6) CD34+ stem cells/kg. Participants will be transplanted with cells obtained from the G-CSF and plerixafor mobilization regimen. The number of CD34+ cells mobilized in the peripheral blood from the time of the plerixafor dose to just prior to apheresis and those harvested in the apheresis product will be measured. The number of apheresis sessions required to obtain ≥ 5*10\^6 CD34+ cells/kg will also be measured. Success of the transplantation(s) will be evaluated by the time to engraftment of poly-morphonuclear leukocytes (PMN) and platelets (PLT). Participants will be followed for durability of their transplant for 12 months following transplantation.

This study was previously posted by AnorMED, Inc. In November 2006, AnorMED, Inc. was acquired by Genzyme Corporation. Genzyme Corporation is the sponsor of the trial.

03

Conditions studied

  • Lymphoma, Non-Hodgkin
  • Multiple Myeloma

Keywords

  • Non-Hodgkin's lymphoma
  • Multiple Myeloma
  • Stem cell mobilization
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of non-Hodgkin's lymphoma (NHL) or multiple myoloma (MM) eligible for transplantation
  • No more than 3 prior regimens of chemotherapy
  • More than 4 weeks since last cycle of chemotherapy. Patient recovered from all acute toxic effects of prior chemotherapy.
  • (ECOG) performance status of 0 or 1
  • White blood cell (WBC) count >3.0*10\^9/L
  • Absolute polymorphonuclear cells (PMN) count >1.5*10\^9/L
  • (PLT) count >100*10\^9/L
  • Serum creatinine \<=2.2 mg/dL
  • Serum glutamic oxaloacetic transaminase (), serum glutamic pyruvic transaminase (SGPT) and total \<2 x (ULN)
  • Left ventricle >45% by normal echocardiogram or multiple-gated acquisition (MUGA) scan
  • Negative for (HIV)
  • Women of child bearing potential who agreed to use an approved form of .

Exclusion criteria

Exclusion Criteria:

  • Patients who have failed previous collections
  • or carcinomatous meningitis
  • History of ventricular arrhythmias
  • History of paresthesias
  • A co-morbid condition which, in the view of the investigator, renders the patient at high risk for treatment complications
  • A residual acute medical condition resulting from prior chemotherapy
  • Acute infection
  • Fever (temp >38°C/100.4°F)
  • Patients whose actual body weight exceeds 150% of their ideal body weight
  • Patients who previously received experimental therapy within 4 weeks of enrolling in this study or who are currently enrolled in another experimental study during the mobilization period
  • Positive pregnancy test in female patients
  • Lactating females
  • Patients of unwilling to implement adequate .
  • Patients who have deterioration of their clinical status or laboratory parameters between the time of enrolment and transplant (such that they no longer meet entry criteria) may be removed from study at the discretion of the treating physician, principal investigator, or sponsor.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Non-Hodgkin's Lymphoma (NHL)

    Participants with NHL were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.

    Drug: G-CSF Plus Plerixafor

  • Experimental
    Multiple Myeloma (MM)

    Participants with MM were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.

    Drug: G-CSF Plus Plerixafor

Interventions

  • DrugG-CSF Plus Plerixafor

    Drug pages: Granulocyte Colony-Stimulating Factor · Plerixafor

    Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.

    Also known as: Mozobil, AMD3100

06

What researchers measure

Primary outcomes

  1. Number of Participants in Overall Safety Summary of Treatment Emergent Adverse Events (TEAE)

    Number of participants with treatment emergent adverse events (TEAEs) collected from Day 1 (start of G-CSF mobilization) to the day before starting chemotherapy (approximately day 38). AEs were graded by the investigator using the World Health Organization (WHO) Adverse Event Grading Scale and were assessed for severity (mild, moderate, severe) and relatedness to study treatment (5 step scale from 'not related' to 'definitely related').

    Time frame: Day 1 to approximately Day 38 (before start of chemotherapy)

Secondary outcomes

  1. Fold (i.e., Relative) Increase in Peripheral Blood (PB) CD34+ Cells/µL After First Dose of Plerixafor

    The fold increase was measured using local lab values and is the ratio of post first dose (pre-apheresis) PB CD34+ cells/µL)/pre-plerixafor dosing PB CD34+ cells/µL)

    Time frame: Days 4-5 (first dose of plerixafor to apheresis)

  2. Number of Transplants in Which Participants Achieved Polymorphonuclear Leukocyte (PMN) Engraftment by Day 12 But No Later Than Day 21 Post Peripheral Blood Stem Cell (PBSC) Transplant

    Participants were monitored for polymorphonuclear leukocyte (PMN) engraftment as per the local standard of care. The target for engraftment was 12 days after PBSC transplant and no transplant taking longer than 21 days for engraftment.

    Time frame: 2 months

  3. Increase in Peripheral Blood (PB) CD34+ Cells From Steady-state Hematopoiesis to Pre-leukapheresis in G-CSF+Plerixafor Treated Participants Compared to Historical Controls Treated With G-CSF Alone or Chemotherapy and G-CSF

    A comparison of the effectiveness in mobilizing peripheral blood CD34+ cells between this study's treatment regimen (G-CSF plus plerixafor) to other treatment options: G-CSF alone, and chemotherapy with G-CSF.

    Time frame: up to day 8

Other outcomes

  1. Median Cumulative Number of CD34+ Cells Collected During Apheresis

    Median total number of CD34+ cells collected during apheresis as measured by a central lab.

    Time frame: Days 5-8

  2. Number of Transplants in Which Participants Achieved Platelet (PLT) Engraftment by Day 12 But No Later Than Day 21 Post Peripheral Blood Stem Cell (PBSC) Transplant

    Participants were monitored for platelet (PLT) engraftment as per the local standard of care. The target for engraftment was 12 days after PBSC transplant and no transplant taking longer than 21 days for engraftment.

    Time frame: 2 months

  3. Number of Participants With Durable Engraftment 12 Months After Transplantation

    The number of participants maintaining a durable graft 12 months after autologous transplantation. A durable graft is defined as the maintenance of normal blood counts.

    Time frame: Approximately 13 months (12 months post-transplant )

07

Results

Posted Nov 25, 2010

Participant flow

Participant flow — Overall Study
MilestoneNon-Hodgkin's Lymphoma (NHL)Multiple Myeloma (MM)
Started431
Completed229
Not completed22
Withdrew: Withdrawal by subject01
Withdrew: Lost to follow-up01
Withdrew: Refused transplant10
Withdrew: Death10

Outcome measures

PrimaryNumber of Participants in Overall Safety Summary of Treatment Emergent Adverse Events (TEAE)

Number of participants with treatment emergent adverse events (TEAEs) collected from Day 1 (start of G-CSF mobilization) to the day before starting chemotherapy (approximately day 38). AEs were graded by the investigator using the World Health Organization (WHO) Adverse Event Grading Scale and were assessed for severity (mild, moderate, severe) and relatedness to study treatment (5 step scale from 'not related' to 'definitely related').

Time frame:
Day 1 to approximately Day 38 (before start of chemotherapy)
Reported as:
Number · participants
Number of Participants in Overall Safety Summary of Treatment Emergent Adverse Events (TEAE)
participantsNon-Hodgkin's Lymphoma (NHL)Multiple Myeloma (MM)All Participants
Participants reporting ≥ 1 AE42024
AE Severity (Mild)21618
AE Severity (Moderate)246
AE Severity (Severe)000
AE Relationship to Drug (Not Related)41822
AE Relationship to Drug (Probably Not Related)000
AE Relationship to Drug (Possibly Related)022
AE Relationship to Drug (Probably Related)000
AE Relationship to Drug (Definitely Related)000
SecondaryFold (i.e., Relative) Increase in Peripheral Blood (PB) CD34+ Cells/µL After First Dose of Plerixafor

The fold increase was measured using local lab values and is the ratio of post first dose (pre-apheresis) PB CD34+ cells/µL)/pre-plerixafor dosing PB CD34+ cells/µL)

Time frame:
Days 4-5 (first dose of plerixafor to apheresis)
Reported as:
Median · ratio
Fold (i.e., Relative) Increase in Peripheral Blood (PB) CD34+ Cells/µL After First Dose of Plerixafor
ratioNon-Hodgkin's Lymphoma (NHL)Multiple Myeloma (MM)All Participants
Fold (i.e., Relative) Increase in Peripheral Blood (PB) CD34+ Cells/µL After First Dose of Plerixafor2.6 ± 1.22.6 ± 1.42.6 ± 1.3
Other pre-specifiedMedian Cumulative Number of CD34+ Cells Collected During Apheresis

Median total number of CD34+ cells collected during apheresis as measured by a central lab.

Time frame:
Days 5-8
Reported as:
Median · CD34+ cells (*10^6 / kg)
Median Cumulative Number of CD34+ Cells Collected During Apheresis
CD34+ cells (*10^6 / kg)Non-Hodgkin's Lymphoma (NHL)Multiple Myeloma (MM)All Participants
Median Cumulative Number of CD34+ Cells Collected During Apheresis8.3 (4.9 to 17.6)7.1 (0.1 to 35.7)7.4 (0.1 to 35.7)
SecondaryNumber of Transplants in Which Participants Achieved Polymorphonuclear Leukocyte (PMN) Engraftment by Day 12 But No Later Than Day 21 Post Peripheral Blood Stem Cell (PBSC) Transplant

Participants were monitored for polymorphonuclear leukocyte (PMN) engraftment as per the local standard of care. The target for engraftment was 12 days after PBSC transplant and no transplant taking longer than 21 days for engraftment.

Time frame:
2 months
Reported as:
Number · number of transplants
Number of Transplants in Which Participants Achieved Polymorphonuclear Leukocyte (PMN) Engraftment by Day 12 But No Later Than Day 21 Post Peripheral Blood Stem Cell (PBSC) Transplant
number of transplantsNon-Hodgkin's Lymphoma (NHL)Multiple Myeloma (MM)All Participants
≤ Day 12088
Day 13 to Day 2122527
≥ Day 22112
Unknown01111
Other pre-specifiedNumber of Transplants in Which Participants Achieved Platelet (PLT) Engraftment by Day 12 But No Later Than Day 21 Post Peripheral Blood Stem Cell (PBSC) Transplant

Participants were monitored for platelet (PLT) engraftment as per the local standard of care. The target for engraftment was 12 days after PBSC transplant and no transplant taking longer than 21 days for engraftment.

Time frame:
2 months
Reported as:
Number · number of transplants
Number of Transplants in Which Participants Achieved Platelet (PLT) Engraftment by Day 12 But No Later Than Day 21 Post Peripheral Blood Stem Cell (PBSC) Transplant
number of transplantsNon-Hodgkin's Lymphoma (NHL)Multiple Myeloma (MM)All Participants
≤ Day 1203232
Day 13 to Day 2121315
≥ Day 22101
Other pre-specifiedNumber of Participants With Durable Engraftment 12 Months After Transplantation

The number of participants maintaining a durable graft 12 months after autologous transplantation. A durable graft is defined as the maintenance of normal blood counts.

Time frame:
Approximately 13 months (12 months post-transplant )
Reported as:
Number · participants
Number of Participants With Durable Engraftment 12 Months After Transplantation
participantsNon-Hodgkin's Lymphoma (NHL)Multiple Myeloma (MM)All Participants
Number of Participants With Durable Engraftment 12 Months After Transplantation22931
SecondaryIncrease in Peripheral Blood (PB) CD34+ Cells From Steady-state Hematopoiesis to Pre-leukapheresis in G-CSF+Plerixafor Treated Participants Compared to Historical Controls Treated With G-CSF Alone or Chemotherapy and G-CSF

A comparison of the effectiveness in mobilizing peripheral blood CD34+ cells between this study's treatment regimen (G-CSF plus plerixafor) to other treatment options: G-CSF alone, and chemotherapy with G-CSF.

Time frame:
up to day 8

No measurements were reported for this outcome.

Adverse events

Collected over First day of G-CSF administration to the day prior to chemotherapy/ablative treatment in preparation of first transplant. This period includes the G-CSF, plerixafor treatment and rest period.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Non-Hodgkin's Lymphoma (NHL)—2/4 (50%)4/4 (100%)
Multiple Myeloma (MM)—0/31 (0%)20/31 (64.5%)
Most frequent serious events
Most frequent serious events
EventNon-Hodgkin's Lymphoma (NHL)Multiple Myeloma (MM)
PyrexiaGeneral disorders1/40/31
Diabetes mellitus non-insulin-dependentMetabolism and nutrition disorders1/40/31
Most frequent other events
Showing 10 of 43
Most frequent other events
EventNon-Hodgkin's Lymphoma (NHL)Multiple Myeloma (MM)
LymphadenopathyBlood and lymphatic system disorders1/40/31
DiarrhoeaGastrointestinal disorders1/42/31
NauseaGastrointestinal disorders1/43/31
AstheniaGeneral disorders1/40/31
PyrexiaGeneral disorders1/43/31
Post procedural diarrhoeaInjury, poisoning and procedural complications1/40/31
ParaesthesiaNervous system disorders1/41/31
HypokalaemiaMetabolism and nutrition disorders0/45/31
VomitingGastrointestinal disorders0/43/31
AnaemiaBlood and lymphatic system disorders0/42/31

Baseline characteristics

Age, Continuous
Age, Continuous(years)Non-Hodgkin's Lymphoma (NHL)Multiple Myeloma (MM)Total
Mean59.8 ± 8.158.8 ± 7.358.9 ± 7.3
Sex: Female, Male
Sex: Female, Male(Participants)Non-Hodgkin's Lymphoma (NHL)Multiple Myeloma (MM)Total
Female31215
Male11920
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Non-Hodgkin's Lymphoma (NHL)Multiple Myeloma (MM)Total
Caucasian43034
Other011
08

Study locations

3 sites
  • University of Cologne
    Cologne, Germany
  • Carl Gustav Carus University Hospital
    Dresden, Germany
  • University of Heidelberg
    Heidelberg, Germany
09

References and documents

Publications

  • Fruehauf S, Seeger T, Maier P, Li L, Weinhardt S, Laufs S, Wagner W, Eckstein V, Bridger G, Calandra G, Wenz F, Zeller WJ, Goldschmidt H, Ho AD. The CXCR4 antagonist AMD3100 releases a subset of G-CSF-primed peripheral blood progenitor cells with specific gene expression characteristics. Exp Hematol. 2006 Aug;34(8):1052-9. doi: 10.1016/j.exphem.2006.06.003. PubMed 16863911 ↗
  • Fruehauf S, Ehninger G, Hubel K, Topaly J, Goldschmidt H, Ho AD, Muller S, Moos M, Badel K, Calandra G. Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients. Bone Marrow Transplant. 2010 Feb;45(2):269-75. doi: 10.1038/bmt.2009.142. Epub 2009 Jul 13. PubMed 19597422 ↗
  • Fruehauf S, Veldwijk MR, Seeger T, Schubert M, Laufs S, Topaly J, Wuchter P, Dillmann F, Eckstein V, Wenz F, Goldschmidt H, Ho AD, Calandra G. A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study. Cytotherapy. 2009;11(8):992-1001. doi: 10.3109/14653240903121245. PubMed 19929463 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2004, a primary completion of Feb 2007 and a completion of Feb 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2010, 3 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2006
First posted
May 8, 2006
Start
Sep 2004
Primary completionActual
Feb 2007
CompletionActual
Feb 2007
Results first posted
Nov 25, 2010
Last update
Mar 13, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00322842
Collaborators
AnorMED
First posted
May 8, 2006
Start date
Sep 2004
Primary completion
Feb 2007
Completion
Feb 2007
Results posted
Nov 25, 2010
Last update
Mar 13, 2014

Study contacts

Medical Monitor
study director · Genzyme, a Sanofi Company
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Granulocyte Colony-Stimulating Factor · Plerixafor

Start the discussion